ROG

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Conference, Digital, Health, Health care, AI, Laboratory, HIMSS, POC, ROG, Pathology

navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.

Key Points: 
  • navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.
  • "Digital advances, such as AI, are transforming healthcare, and we have exciting new opportunities to increase the speed of diagnosis and improve outcomes for patients,"  said Moritz Hartmann, Global Head of Roche Information Solutions at Roche Diagnostics.
  • At HIMSS (Roche Booth#2911), Roche will present its full array of navify digital solutions, an integrated and secure set of solutions that delivers connectivity and data-driven insights to enhance efficiency and interoperability in healthcare.
  • Roche and external speakers will also discuss the impact of digital transformation in healthcare from screening, diagnosis, to personalised care including:

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Conference, Digital, Health, Health care, AI, Laboratory, HIMSS, POC, ROG, Pathology

navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.

Key Points: 
  • navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.
  • "Digital advances, such as AI, are transforming healthcare, and we have exciting new opportunities to increase the speed of diagnosis and improve outcomes for patients,"  said Moritz Hartmann, Global Head of Roche Information Solutions at Roche Diagnostics.
  • At HIMSS (Roche Booth#2911), Roche will present its full array of navify digital solutions, an integrated and secure set of solutions that delivers connectivity and data-driven insights to enhance efficiency and interoperability in healthcare.
  • Roche and external speakers will also discuss the impact of digital transformation in healthcare from screening, diagnosis, to personalised care including:

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

Retrieved on: 
Sunday, February 25, 2024
Teens, Women, Children, Men, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Bangladesh Technical Education Board, AAAAI, Johns Hopkins Children's Center, Research, Food allergy, Hazelnut, NIH, FDA, Food, Immunoglobulin E, Rheumatology, NEJM, Risk, Annual general meeting, Safety, Roche, Milk, ROG, Fear, Patient, Medicine, Asthma, Face, American Academy, Pharmaceutical industry

Safety findings were consistent with the known safety profile of Xolair across its approved indications and in previous clinical trials.

Key Points: 
  • Safety findings were consistent with the known safety profile of Xolair across its approved indications and in previous clinical trials.
  • The U.S. Food and Drug Administration (FDA) recently approved the expanded use of Xolair in children and adults with IgE-mediated food allergies based on the OUtMATCH data.
  • “While allergic reactions to exposures are common and often severe, there have been limited treatment advancements for food allergy.
  • “The OUtMATCH study demonstrated that anti-IgE therapy increased most patients’ threshold for an allergic reaction.

Rogers Corporation Announces New Factory in Monterrey, Mexico

Retrieved on: 
Thursday, February 22, 2024
Alternative Energy, EV, Electric Vehicles, Energy, Automotive, Engineering, Technology, Manufacturing, Other Technology, AES, Senior, Renewable energy, ROG, Rogers Corporation, Investment

Rogers Corporation (NYSE: ROG) announced today that it has signed a lease on a factory in Monterrey, Mexico for advanced busbar manufacturing and engineering services.

Key Points: 
  • Rogers Corporation (NYSE: ROG) announced today that it has signed a lease on a factory in Monterrey, Mexico for advanced busbar manufacturing and engineering services.
  • The first phase of the new site is slated for completion in late 2024 and continues Rogers’ manufacturing footprint strategy of supporting customers in the regions where they operate.
  • Rogers’ advanced ROLINX® busbars provide effective and efficient power distribution in a variety of applications in the electric and hybrid-electric vehicle (EV/HEV), renewable energy, mass transit and industrial markets.
  • Customers choose ROLINX® busbars based on Rogers’ proven quality and reliability, electrical and mechanical expertise, co-engineering support and flexible lead times.

Asetek - Q4 2023: Liquid Cooling Demand and SimSports Expansion Driving Growth

Retrieved on: 
Friday, March 8, 2024
Depreciation, ASUS, OEM, USD, Growth, HQ, Liquid cooling, Nasdaq Copenhagen, ROG, Uncertainty, Q&A, CPU, Video game

The growth in both periods mainly reflects increased shipments of liquid cooling products.

Key Points: 
  • The growth in both periods mainly reflects increased shipments of liquid cooling products.
  • "2023 represented a material rebound for our Liquid Cooling business and expansion of the SimSports product program to wide acclaim from the sim racing community.
  • In the first quarter of 2024, ten new liquid cooling products and various new SimSports accessories are expected to begin shipping.
  • Larger customers have expressed increased demand for Liquid Cooling products with a lower price point for the Chinese market as well as other value-oriented markets.

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

Retrieved on: 
Friday, February 16, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Infection, Allergy, Bangladesh Technical Education Board, AAAAI, Johns Hopkins Children's Center, Emergency, Hazelnut, NIAID, American Academy, Omalizumab, NIH, Friends, Food, Immunoglobulin E, News, Asthma, Anaphylaxis, FARE, Annual general meeting, Prevalence, Roche, Milk, ROG, AAFA, Patient, Family, Phase, Ageing, Education

People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”).

Key Points: 
  • People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”).
  • Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterized by the rapid onset of symptoms following exposure to certain food allergens.
  • Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies.
  • About 3.4 million children and 13.6 million adults in the U.S. have been diagnosed with IgE-mediated food allergies, based on estimates for 2024.

Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Marie Cassidy, Algorithm, Artificial intelligence, Intelligence, Pathology, Drug development, Digital pathology, Digital, Entrepreneurship, RTD, ROG, Diagnosis, Laboratory, Workflow, Medical imaging

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.

Key Points: 
  • PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
  • The image analysis algorithms will be deployed on Roche's navify Digital Pathology platform, allowing seamless integration into pathology laboratories worldwide.
  • The collaboration between RTD and PathAI helps advance precision medicine by bringing together AI-interpretation and companion diagnostics, increasing patient access to targeted treatments.
  • Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space.

Pixelmon Brings Fully Decentralized Monster IP Vision to Immutable

Retrieved on: 
Monday, February 12, 2024
EVM, Collection, Polygon, Player versus environment, News, RPG, NFT, PvP, ROG, Ecosystem, First generation, Intellectual property, IP, ZK, Partnership, Video game

SYDNEY, Feb. 12, 2024 /PRNewswire/ -- Immutable, the leading web3 gaming platform and ecosystem, today announced a partnership with LiquidX, the studio behind revitalized battle arena game Pixelmon, which is set to launch on the recently released Immutable zkEVM. The LiquidX team aims to build the world's first truly decentralized intellectual property (IP) for monster capture and combat, beginning with a four-part relaunch roadmap.

Key Points: 
  • The LiquidX team aims to build the world's first truly decentralized intellectual property (IP) for monster capture and combat, beginning with a four-part relaunch roadmap.
  • As the second-highest gaming NFT by transaction volume on OpenSea, anticipation for Pixelmon remains high amongst web3 gamers.
  • Under new leadership from LiquidX co-founder Giulio Xiloyannis, Pixelmon is gearing up to deliver a fast-paced monster combat experience.
  • This will lead to an open-world RPG launch and ultimately, a fully decentralized multiplayer metaverse owned by the Pixelmon community.

Rogers Schedules Fourth Quarter 2023 Earnings Call for February 21

Retrieved on: 
Thursday, February 8, 2024
Technology, Other Manufacturing, Other Technology, Manufacturing, Rogers Corporation, Senior, ROG

Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce fourth quarter and full year 2023 results on February 21, 2024 after market close, which will be followed by a conference call at 5:00 pm ET.

Key Points: 
  • Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce fourth quarter and full year 2023 results on February 21, 2024 after market close, which will be followed by a conference call at 5:00 pm ET.
  • The call will be hosted by Colin Gouveia, President and Chief Executive Officer, who will be joined by Ram Mayampurath, Senior Vice President and Chief Financial Officer.
  • A live webcast of the event and related slide presentation can be accessed on Rogers’ Investor Relations website at https://rogerscorp.com/investors .
  • A replay of the event will also be available on the Investor Relations’ website.

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Paratriathlon, Inflammation, Ranibizumab, Research, Ophthalmology, RVO, Patient, Diabetic retinopathy, Swelling, CRVO, BRVO, Food, ROG, Bascom Palmer Eye Institute, Retina, Blood, Macular edema, Angiogenesis, Roche, Eye, CST, Telescopic sight

In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.

Key Points: 
  • In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year.
  • Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.
  • In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.
  • “The sustained vision improvements and retinal drying seen up to 72 weeks reaffirm Vabysmo as an effective treatment for retinal vein occlusion,” said Ramin Tadayoni, M.D., Ph.D., head of ophthalmology at Université Paris Cité in Paris and president of EURETINA, who is presenting the data at Angiogenesis.